carbamates has been researched along with Hypertension, Portal in 5 studies
Hypertension, Portal: Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Portal hypertension is the strongest predictor of virological response to pegylated interferon (IFN)/ribavirin in patients with chronic hepatitis C (CHC)-related cirrhosis." | 3.81 | Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses. ( Beinhardt, S; Ferenci, P; Ferlitsch, A; Freissmuth, C; Hofer, H; Kozbial, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Schwabl, P; Schwarzer, R; Stättermayer, AF; Trauner, M, 2015) |
| "Excellent SVR12 rates and the favorable side-effect profile of DAA-combination therapy can be well translated into "real-world"." | 1.43 | Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. ( Beck, R; Berg, CP; Egetemeyr, DP; Lauer, UM; Malek, NP; Schwarz, JM; Werner, CR, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mangia, A | 1 |
| Cenderello, G | 1 |
| Copetti, M | 1 |
| Verucchi, G | 1 |
| Piazzolla, V | 1 |
| Lorusso, C | 1 |
| Santoro, R | 1 |
| Squillante, MM | 1 |
| Orlandini, A | 1 |
| Minisini, R | 1 |
| Ciancio, A | 1 |
| Mandorfer, M | 1 |
| Kozbial, K | 1 |
| Freissmuth, C | 1 |
| Schwabl, P | 1 |
| Stättermayer, AF | 1 |
| Reiberger, T | 1 |
| Beinhardt, S | 1 |
| Schwarzer, R | 1 |
| Trauner, M | 1 |
| Ferlitsch, A | 1 |
| Hofer, H | 1 |
| Peck-Radosavljevic, M | 1 |
| Ferenci, P | 2 |
| Forns, X | 1 |
| Poordad, F | 1 |
| Pedrosa, M | 1 |
| Berenguer, M | 1 |
| Wedemeyer, H | 1 |
| Shiffman, ML | 1 |
| Fried, MW | 1 |
| Lovell, S | 1 |
| Trinh, R | 1 |
| Lopez-Talavera, JC | 1 |
| Everson, G | 1 |
| Renard, S | 1 |
| Borentain, P | 1 |
| Salaun, E | 1 |
| Benhaourech, S | 1 |
| Maille, B | 1 |
| Darque, A | 1 |
| Bregigeon, S | 1 |
| Colson, P | 1 |
| Laugier, D | 1 |
| Gaubert, MR | 1 |
| Habib, G | 1 |
| Werner, CR | 1 |
| Schwarz, JM | 1 |
| Egetemeyr, DP | 1 |
| Beck, R | 1 |
| Malek, NP | 1 |
| Lauer, UM | 1 |
| Berg, CP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOIS[NCT01704755] | Phase 3 | 381 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log(subscript)10(subscript) IU/mL above the lowest value post baseline] at any time point during treatment), or fail to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01704755)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 0.5 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 1.7 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01704755)
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 91.8 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 96.5 |
A sustained virologic response is defined as plasma Hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (< LLOQ) 12 weeks after the last dose of study drug. (NCT01704755)
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 91.8 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 96.5 |
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma Hepatitis C virus ribonucleic acid (HCV RNA) ≥ lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment. (NCT01704755)
Timeframe: within 12 weeks after the last dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 5.9 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 0.6 |
2 trials available for carbamates and Hypertension, Portal
| Article | Year |
|---|---|
SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study.
Topics: Adult; Aged; Carbamates; Cohort Studies; Comorbidity; Female; Hepacivirus; Heterocyclic Compounds, 4 | 2019 |
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dru | 2015 |
3 other studies available for carbamates and Hypertension, Portal
| Article | Year |
|---|---|
Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; | 2015 |
Severe Pulmonary Arterial Hypertension in Patients Treated for Hepatitis C With Sofosbuvir.
Topics: Antiviral Agents; Carbamates; Comorbidity; Drug Therapy, Combination; Female; Hepatitis C, Chronic; | 2016 |
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; H | 2016 |